Combination treatment for advanced or relapsed lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests a new combination of two drugs, almonertinib and SHR-1701, for people with advanced non-small cell lung cancer that has come back or spread. The goal is to see if this combination can help control the cancer and is safe to use.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced or relapsed non-small cell lung cancer confirmed by biopsy or other tests.
- You have at least one tumor that can be measured on scans.
- You are able to care for yourself (performance status 0 or 1).
- You have not had certain untreated brain metastases causing symptoms, uncontrolled fluid buildup, or recent bleeding problems.
- You do not have active autoimmune diseases, uncontrolled heart conditions, or active infections that require intravenous treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs (almonertinib and anlotinib) as first treatment for advanced non-small cell lung cancer that has specific gene changes (EGFR and TP53 mutations). The goal is to see if the pair works better than standard care.
This Phase 3 trial tests whether almonertinib given after standard chemoradiation can help people with stage III, non-surgical lung cancer live longer and/or control the cancer. It is for tumors with specific EGFR mutations linked to sensitivity to EGFR-targeted medicines.
This trial tests a new drug called SHR-1826 in combination with other anti-cancer therapies for people with non-small cell lung cancer (NSCLC). It aims to see if these combinations are safe and effective for patients who haven't been treated before or whose cancer has come back.
This trial tests a new drug, SHR-A2102, combined with other treatments for people with non-small cell lung cancer that can be removed with surgery. It aims to improve outcomes by using multiple therapies together.
This trial is testing a new experimental drug (called TQB2928) combined with a standard targeted therapy pill for people with advanced non-small cell lung cancer that has an EGFR mutation. The goal is to see if this combination can help when standard EGFR inhibitors are no longer effective.
This study tests whether almonertinib taken after complete surgery can improve outcomes for people with stage II–IIIA non-small cell lung cancer (NSCLC) that has certain EGFR gene changes. It also compares almonertinib plus chemotherapy versus almonertinib alone to see which approach is safer and works better.
Hear when a new Relapsed or Advanced Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.